The identification of the V474I variant as a hypermorphic driver of these processes underscores the importance of germline genetics in shaping metastatic outcomes and provides a compelling rationale for targeting PCSK9 in high-risk breast cancer patients. This evidence concerns the gene PCSK9 and breast carcinoma.